These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37286407)

  • 1. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
    Yanai T; Yoshida S; Takeuchi M; Kawakami K
    Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term impact of pneumococcal conjugate vaccines for children on adult pneumococcal pneumonia in Japan: Two multicenter observational studies from 2011 to 2020.
    Maeda H; Gopal Dhoubhadel B; Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
    Vaccine; 2022 Sep; 40(37):5504-5512. PubMed ID: 35963821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pneumococcal conjugate vaccine in children morbidity and mortality in Peru: Time series analyses.
    Suarez V; Michel F; Toscano CM; Bierrenbach AL; Gonzales M; Alencar AP; Ruiz Matus C; Andrus JK; de Oliveira LH
    Vaccine; 2016 Sep; 34(39):4738-4743. PubMed ID: 27521230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the introduction of pneumococcal conjugate vaccination on pneumonia in The Gambia: population-based surveillance and case-control studies.
    Mackenzie GA; Hill PC; Sahito SM; Jeffries DJ; Hossain I; Bottomley C; Uchendu U; Ameh D; Ndiaye M; Osuorah CD; Adeyemi O; Pathirana J; Olatunji Y; Abatan B; Ahameefula E; Muhammad BS; Fombah AE; Saha D; Mackenzie R; Plumb I; Akano A; Ebruke B; Ideh RC; Kuti B; Githua P; Olutunde E; Ofordile O; Green E; Usuf E; Badji H; Ikumapayi UNA; Manjang A; Salaudeen R; Nsekpong ED; Jarju S; Antonio M; Sambou S; Ceesay L; Lowe-Jallow Y; Sowe D; Jasseh M; Mulholland K; Knoll M; Levine OS; Howie SR; Adegbola RA; Greenwood BM; Corrah T
    Lancet Infect Dis; 2017 Sep; 17(9):965-973. PubMed ID: 28601421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
    Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
    Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of infant pneumococcal conjugate vaccination on community acquired pneumonia hospitalization in all ages in the Netherlands.
    van Deursen AMM; Schurink-Van't Klooster TM; Man WH; van de Kassteele J; van Gageldonk-Lafeber AB; Bruijning-Verhagen PCJL; de Melker HE; Sanders EAM; Knol MJ
    Vaccine; 2017 Dec; 35(51):7107-7113. PubMed ID: 29146381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
    Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
    Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indirect effect of 7-valent and 13-valent pneumococcal conjugated vaccines on pneumococcal pneumonia hospitalizations in elderly.
    Kislaya I; Rodrigues AP; Sousa-Uva M; Gómez V; Gonçalves P; Froes F; Nunes B
    PLoS One; 2019; 14(1):e0209428. PubMed ID: 30650091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pneumococcal conjugate vaccines on acute otitis media in Japan.
    Sasaki A; Kunimoto M; Takeno S; Sumiya T; Ishino T; Sugino H; Hirakawa K
    Auris Nasus Larynx; 2018 Aug; 45(4):718-721. PubMed ID: 29102419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of pneumococcal conjugate vaccine on the prevalence and severity of hospitalizations for pneumonia in children.
    Eichler N; Joseph L; Megged O; Goldberg S; Picard E
    Eur J Clin Microbiol Infect Dis; 2022 Mar; 41(3):439-444. PubMed ID: 34997390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of implementing the 10-valent pneumococcal conjugate vaccine on hospitalizations for pneumonia among children.
    de Melo Araujo AC; da Silva Aragão J; de Souza WV; Rodrigues LC; de Barros Miranda-Filho D
    Vaccine; 2023 Jul; 41(32):4719-4725. PubMed ID: 37353456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
    Wiese AD; Griffin MR; Zhu Y; Mitchel EF; Grijalva CG
    Vaccine; 2016 Dec; 34(50):6243-6249. PubMed ID: 27832918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
    Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
    Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.